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‘‘I came, I saw, I conquered,’’ Julius Caesar proclaimed, highlighting the importance of direct visual-
ization as a winning strategy. Continuing the ‘‘From the Field’’ series (see Editorial [2007] 26, 131),
Gross et al. summarize howmodernmolecular imaging techniques can successfully dissect the com-
plexities of immune response in vivo.In Vivo Imaging and Immunology:
A Perfect Match
The vertebrate immune system is ex-
tremely complex and highly dynamic.
This complexity provides the basis
for its capacity to recognize, respond,
and remember pathogenic assaults,
thereby providing the host with re-
markable surveillance and protection
mechanisms in an exogenously and
endogenously hostile environment (i.e.,
pathogenic infections and malignant
transformations, respectively). The
vast majority of cells comprising our
immune system are motile, migrating
between the bone marrow (BM),
bloodstream, secondary lymphoid or-
gans, and affected tissues or organs.
In addition, immune cells undergo
tightly regulated, interaction-depen-
dent activities (clonal expansion and
depletion, transdifferentiation, and
chemotaxis) that are aimed at the pro-
duction, maintenance, and resolution
of a proper immune reaction.
Surprisingly, knowledge of the im-
mune system has largely originated
from static endpoint experiments that
provide ‘‘snapshots’’ of this complex
activity (e.g., cytometry, histology, and
solution biochemistry) (Germain et al.,
2006; Negrin and Contag, 2006). Al-
though important information has
been gathered from these types of
experiments, detailed and accurate
studies of the regulatory dynamics of
the immune system in real-time are
lacking and require the capacity to
temporally and spatially resolve spe-
cific immune reactions within an intact
animal. Furthermore, until not long
ago, our understanding of the factorsthat regulate migration and trafficking
of immune cells had been obtained
from cultured cells, likely under-repre-
senting the influences of the complex
milieu in which immune reactions take
place in vivo (e.g., transendothelial
trafficking, endocrine and paracrine
regulation, stromal interactions, circu-
lation, oxidative state, etc.). Recent
advances in cellular and molecular
biology combined with noninvasive
imaging technologies and strategies
hold great promise for providing im-
munologists with new insights into
the systemic regulation and dynamics
of the immune machinery in both
health and disease.
Brief Overview of Imaging
Modalities and Strategies
Historically, radiology and imaging sci-
ences were developed for diagnostic
purposes, providing the clinical practi-
tioner with an eyepiece to noninva-
sively detect anatomical disorders.
However, today’s imaging strategies
play a much broader role and are ap-
plied to basic research paradigms,
discovery, development and optimiza-
tion of novel therapeutics, as well as
to translational research and clinical
diagnostics (Gross and Piwnica-
Worms, 2005b; Tsien, 2003). Devel-
opment of novel probes, genetically
encoded reporters, and biomarkers
extend the ability to track a particular
biological event (molecular, cellular,
or physiological, not only anatomical)
by means of noninvasive imaging and
open a whole new arena to investi-
gate complex biological processes
in vivo.Immunity 2Imaging modalities provide valuable
information that differ in temporal
(milliseconds to hours) and spatial
(microns to centimeters) resolution,
as well as in other technical aspects
(tissue penetration, biochemical sensi-
tivity, signal-to-noise, tomographic
[cross-sectional] potential, through-
put, cost, ease of operation, and clini-
cal translatability). Therefore, experi-
ments should be carefully designed
to best match the biological question
of interest with the appropriate tech-
nology. The various noninvasive mo-
lecular imaging modalities can be
categorized as optical, nuclear, and
magnetic resonance imaging (MRI),
each of which can be combined
together in fusion imaging strategies
or combined with X-ray computed to-
mography (CT) or ultrasound imaging
(i.e., multimodal imaging) to merge
molecular function, sensitivity, and
spatial resolution. In brief, macro-
scopic optical modalities (whole-body
bioluminescence or fluorescence im-
aging) exhibit excellent biochemical
sensitivity and throughput and allow
enzyme-mediated probe activation
strategies and multicolor multiplexing,
but show limited spatial resolution.
Microscopic optical modalities (e.g.,
intravital two-photon microscopy,
intravital fluorescence microscopy)
can provide extraordinary spatial
resolution (single cell, micron) and
temporal resolution (subsecond rate
constants), but can be somewhat inva-
sive, limited to superficial structures,
demand highly sophisticated instru-
mentation and qualified personnel,
and are highly susceptible to motion7, October 2007 ª2007 Elsevier Inc. 533
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Commentaryartifacts. Nuclear modalities, such as
positron emission tomography (PET)
and single-photon emission computed
tomography (SPECT), offer excep-
tional biochemical sensitivity (i.e., the
capacity to detect picomolar concen-
trations of target upon injection of min-
imal amounts of radiotracer), are quan-
titative and inherently tomographic,
but suffer from limited spatiotemporal
resolution and generally require on-
site synthesis of radiolabeled tracers
with the need for committed person-
nel. MRI offers multiplanar tomo-
graphic display, high spatial resolution
at high magnetic fields, and (like nu-
clear modalities) can be directly trans-
lated to clinical applications, but is
hindered by low sensitivity to biochem-
ical and molecular processes, low
throughput, and high cost. Commonly,
instruments scaled for animal studies
(microPET, nanoSPECT, microCT,
etc.) are generally available to investi-
gators at major research institutions.
The advantages, limitations, technical
challenges, and enhancements under
investigation for each of the various
imaging modalities are addressed in
several in-depth reviews (Gross and
Piwnica-Worms, 2005b; Negrin and
Contag, 2006; Tsien, 2003) and are
summarized in Table 1. Herein, we
will briefly review examples of mo-
lecular imaging strategies, focusing
on injectable probes and genetically
encoded reporters in the context of
immunological paradigms, with the
intent to inspire future innovations to
visualize and conquer open questions
in immunology.
Imaging Innate Immunity
Innate immune defenses consist of
cellular (leukocyte) mechanisms as
well as chemical and humoral (inflam-
mation and complement system) re-
sponses, each of which present viable
targets for imaging. Genetic or chemi-
cal labeling of leukocytes (in vivo or
ex vivo), followed by transfer to recipi-
ent animals, allows the dynamic moni-
toring of trafficking and accumulation
of leukocytes into inflammatory sites.
For example, Swirski and colleagues
used fluorescence and nuclear imag-
ing techniques to monitor infiltration
of monocytes at atherogenic foci by
adaptive transfer of monocytes from534 Immunity 27, October 2007 ª2007 EGFP-expressing mice and by ex vivo
labeling with 111In-oxine, respectively
(Swirski et al., 2006). In another
example, Nakamichi et al. transferred
Mac1+ macrophages from luciferase
pan-expressing mice to hemin-treated
recipients and demonstrated that
hemin activates heme-oxygenase 1
(HO-1) in peritoneal macrophages,
thereby inducing macrophage recruit-
ment to the pancreas and conferring
protection against pancreatitis (Naka-
michi et al., 2005).
Imaging strategies can also resolve
inflammation-associated enzyme ac-
tivities in vivo at various spatial scales
depending on the modality and probe
design. One prototypic design in-
volves activatable optical imaging
agents, which typically exist in a basal
‘‘off’’ state mediated by resonance en-
ergy transfer between a donor fluoro-
phore and an acceptor, resulting in
inter- or intramolecular quenching. If an
enzyme (protease) acts on a cleavable
moiety synthesized between the donor
and acceptor, release of the fluoro-
phore ‘‘signals’’ the presence of the
target enzyme. These activation strat-
egies (and an analogous process with
MRI contrast agents) can theoretically
reduce background noise and pro-
duce sensitive and specific images of
enzyme activities in vivo. For example,
in a recent study, Jaffer and col-
leagues imaged elastolytic activity of
the extracellular cysteine protease
cathepsin K (CatK) in an atheroma
inflammation model by using a near-
infrared fluorescence (NIRF) imaging
agent consisting of the CatK peptide
substrate GHPGGPQGKC-NH2 linked
to an activatable fluorogenic polymer
(Jaffer et al., 2007). As applied in this
model, multiwavelength intravital fluo-
rescence microscopy allowed detec-
tion of CatK activity and a spectrally
resolved intravascular agent within in-
tact exposed atherosclerotic vessels
at submillimeter resolution. Similar
strategies with fluorescently labeled,
cell-permeable activatable peptides
were also employed in whole-body
fluorescence imaging to monitor
regional caspase-3 activity during
parasite-induced apoptosis in colon
xenograft and liver abscess mouse
models (Bullok et al., 2007). In another
innovative example, Chen et al. werelsevier Inc.able to image by MRI at subcentimeter
resolution LPS-induced myeloperoxi-
dase activity in a murine myositis
model by low-molecular-weight probes
that polymerized upon peroxidation.
This in vivo polymerization strategy
increased paramagnetic relaxivity and
enhanced protein binding to generate
MRI contrast in response to acute in-
flammation (Chen et al., 2006).
Another viable strategy is to label,
inject, and image chemotactic and
chemokinetic compounds that are
expected to accumulate at sites of
inflammation. These bioactive sub-
stances include cytokines, prostaglan-
dins, leukotrienes, or synthetic antag-
onists or partial agonists of such
ligands. For example, it was demon-
strated that scintigraphic imaging after
intravenous administration of an 111In-
or 99mTc-labeled leukotriene B4 antag-
onist reveals acute infectious and in-
flammatory lesions in various rabbit
models (Figure 1A; van Eerd et al.,
2004). In another recent study, Kauf-
mann et al. utilized contrast-enhanced
ultrasonic imaging to visualize micro-
bubbles conjugated to monoclonal
antibodies directed against vascular
cell adhesion molecule-1 (VCAM-1) to
noninvasively detect and quantify in-
flammatory, VCAM-1-positive athero-
sclerotic plaques in mice (Kaufmann
et al., 2007).
Noninvasive imaging also allows
study of gross physiological changes
associated with inflammatory pro-
cesses. For example, MRI can detect
regional changes in water diffusion
as a result of inflammation-induced
edema (Lazovic et al., 2005), and
18F-deoxyglucose (FDG) PET can
point to regions with cellular infiltrates
and increased metabolic activities. In-
deed, although nonspecific, FDG PET
is clinically sensitive and useful for lo-
calizing sources of fever of unknown
origin (FUO), monitoring progression
and response to treatment in cases
of sarcoidosis and vasculitis, and diag-
nosing osteomyelitis (for a review, see
Love et al., 2005).
Imaging Adaptive Immunity
Molecular imaging offers powerful
strategies to investigate complex ac-
tivities mediated by the adaptive
immune system, sometimes providing
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able by conventional techniques. For
example, provocative studies utilizing
microPET imaging to follow injected,
radiolabeled arthritogenic autoanti-
bodies in mice surprisingly revealed
immediate localization of the probe to
commonly affected joints, indicating
that the antigen likely pre-existed in
an accessible form at the inflamed
joints (Figure 1B; Wipke et al., 2002).
This further suggested that a tissue-
specific immune response can be initi-
ated against a ubiquitously expressed
antigen. Additional imaging studies
with this labeled antibody have
demonstrated the necessity of innate
immunity factors (mast cells, neutro-
phils, immune complexes) for permit-
ting access of autoantibodies to
the joints, where they subsequently
bind their cognate antigen and initiate
inflammation (Wipke et al., 2004).
Both in vivo and ex vivo imaging of
luciferase-labeled immune cells have
been utilized to study graft versus
host disease (GVHD). Luciferase-ex-
pressing allogeneic splenocytes were
transplanted along with BM cells to
induce acute lethal GVHD; biolumines-
cence imaging (BLI) could com-
prehensively monitor donor cell ex-
pansion, migration, and infiltration
into GVHD target tissues in vivo (Beil-
hack et al., 2005). Ex vivo BLI permit-
ted even more precise localization of
donor cell infiltrates, which in turn
enabled specific sampling and analy-
sis (by FACS and histology) of BLI-
positive tissues. In this case, Peyer’s
patches that had disappeared macro-
scopically (due to host animal irra-
diation prior to transplantation) were
rendered accessible to further analysis
by BLI-guided tissue sampling, thereby
enhancing analysis beyond conven-
tional approaches.
On a different scale, two-photon in-
travital microscopy has been utilized
to study the behavior of single immune
cells in intact or explanted lymph
nodes in vivo. This technique was
recently applied in groundbreaking
studies aimed at deciphering the dy-
namics, motility, and cell-cell interac-
tions of B cells and T cells in germinal
centers of lymph nodes (Allen et al.,
2007), thereby elucidating the com-
plex behavior of these cells in an27, October 2007 ª2007 Elsevier Inc. 535
Immunity
CommentaryFigure 1. Selected Examples of Molecular Imaging Strategies to Investigate
Immune Response In Vivo
(A and B) Imaging innate and adaptive immunity with injectable probes.
(A) g-scintigraphic images acquired at the indicated times after injection of 111In-DPC11870 (radio-
labeled leukotriene antagonist) in a rabbit with acute colitis. Note the strong intestinal signal emit-
ted as soon as 1–2 hr after administration of the probe (arrows) (reprinted by permission of the
Society of Nuclear Medicine from van Eerd et al., 2004).
(B) PET imaging after injection of 64Cu-labeled anti-glucose-6-phosphate-isomerase (GPI) IgG
(left) or control IgG (right). Note the substantial accumulation of anti-GPI IgG in the joints (arrows)
(adapted by permission from Macmillan Publishers Ltd: Nature Immunology [Wipke et al., 2002]).
(C) Dynamic imaging of single immune cell interactions in vivo with fluorescent reporters and
2-photon intravital microscopy. Time-lapse images of a transient interaction between a GFP-
tagged B cell and a CFP-tagged T cell in the dark zone of the germinal center (GC) in an intact
lymph node in vivo (from Allen et al., 2007; reprinted with permission from AAAS).
(D) Visualizing transcriptional activity in vivo by expression of an imaging reporter gene. By biolu-
minescence imaging (BLI), global Smad2 and Smad3 transcriptional activity was measured in
pSBE/FLuc pan-expressing mice upon treatment with LPS (reprinted from Lin et al., 2005).
(E) Imaging immune-mediated signaling cascades in real-time with post-translationally modified
fusion reporters (induced protein degradation and stabilization). BLI of bortezomib-mediated
modulation of LPS-induced IKK activity in vivo. A reporter of IKK activity (IkBa-FLuc) was delivered
to hepatocytes by hydrodynamic somatic gene-transfer techniques. Mice were then imaged after
the indicated treatments. Note that bortezomib not only abrogated LPS-induced activation of IKK
(degradation of IkBa-FLuc), but actually promoted reporter accumulation, consistent with inhibi-
tion of both ligand-induced degradation and basal turnover of IkBa (reprinted by permission
from Macmillan Publishers Ltd: Nature Methods [Gross and Piwnica-Worms, 2005a]).antigen-dependent manner within
their normal environment (Figure 1C).
Imaging Host-Pathogen
Interactions
The molecular imaging toolbox offers
researchers noninvasive means to
characterize host-pathogen interac-
tions within living animals. For exam-
ple, bioluminescent viral strains can
be utilized to follow viral replication
and localization in individual intact an-
imals and to investigate viral and host536 Immunity 27, October 2007 ª2007 Efactors that govern pathogenesis. A
recombinant, fully virulent vaccinia
virus expressing firefly luciferase
(Vac-FLuc) was generated to investi-
gate the extent to which interferons
regulate replication and dissemination
of vaccinia in vivo (Luker et al., 2005).
The authors found that replication
of vaccinia virus was substantially
greater in mice lacking type 1 inter-
feron receptors (Ifnar1/) and that
type 1 interferon affects dissemination
of vaccinia from the respiratory systemlsevier Inc.to systemic sites such as liver and
spleen. BM transplants from wild-
type animals to Ifnar1/ animals
showed substantially higher vaccinia
infections compared to wild-type
animals transplanted with Ifnar1/
marrow, indicating that the protective
effects of type 1 interferons are medi-
ated primarily through parenchymal
rather than hematopoietic cells. Thus,
use of BLI in this study uniquely al-
lowed for (1) facile quantification of
the spatial and temporal progression
of vaccinia infection in the context of
different genetic backgrounds of the
host and (2) detection of unexpected
patterns of viral dissemination in vivo
in individual animals.
A second means of investigating
host-pathogen interactions is by the
use of transgenic mice that express
a genetically encoded imaging re-
porter driven by a pathogen-respon-
sive promoter. This strategy bypasses
the need to construct reporter patho-
gens (which may be attenuated com-
pared to their parental strain), allowing
facile examination of a variety of path-
ogenic strains. This approach was uti-
lized to study the spatial and temporal
progression of infection and the rela-
tive degree of virulence when three
variants of herpes simplex virus 1
(HSV-1) were introduced into the cor-
nea or flank of mice expressing FLuc
under control of the HSV-1 thymidine
kinase promoter (Luker et al., 2006).
Imaging Immunity-Related
Signal Transduction
Numerous signaling pathways are im-
plicated in activation and suppression
of both innate and adaptive immunity,
and therefore, improper regulation of
these signaling cascades may lead
to pathological immune responses.
Integration of imaging, signal trans-
duction, and use of animal models of
immunity, inflammation, or immuno-
logical disorders is already enhancing
our understanding of specific signaling
events in normal and pathological
immune responses.
Specifically, signaling events can
be visualized in live immune cells by
placing an ‘‘imagable’’ reporter gene
downstream of a stimulus-specific
inducible promoter such that ob-
served outputs are a function of
Immunity
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promoter and therefore reflect activity
of the associated upstream signaling
cascades. For example, gene expres-
sion can be visualized by a b-lacta-
mase reporter that can hydrolyze a
membrane-permeant fluorogenic sub-
strate, changing the substrate fluores-
cence from green to blue (Zlokarnik
et al., 1998). This system was used
for quantitative analysis of M1 musca-
rinic receptor agonist-induced NF-AT
transcriptional activity in intact T cells.
Further, temporal and spatial pat-
terns of signaling can be studied
in vivo with transgenic mice express-
ing an imagable reporter. For example,
to characterize Smad2- and Smad3-
dependent signaling in intact animals,
a transgenic mouse was generated
wherein FLuc was driven by a Smad-
responsive element (pSBE/FLuc)
(Figure 1D; Lin et al., 2005). With BLI,
the authors were able to noninvasively
assess global and organ-specific
changes in TGFb and Smad2- and
Smad3-dependent signaling upon
systemic administration of lipopoly-
saccharide (LPS) or induction of trau-
matic brain injury, respectively, and
revealed important but different re-
sponses to LPS in specific organs.
Similarly, spatial and temporal changes
in response to sepsis, acute arthritis,
and contact hypersensitivity were
monitored by BLI in transgenic mice
with a serum amyloid A-driven lucifer-
ase reporter (pSAA/FLuc) (Zhang
et al., 2005). When used in this way,
note that BLI is useful for gross organ
localization of responses, but not for
the fine mapping that connects the re-
sponse to a cell type or even a region
with limited cell types. For this reason,
under development are second-gen-
eration reporter mice that express lu-
ciferase-GFP fusion proteins, thereby
enabling rapid, noninvasive regional
analysis by BLI and concordant cell
type-specific analysis by fluorescence
microscopy or FACS.
To monitor organ-related changes in
the activity of NF-kB, a transcription
factor that regulates many inflamma-
tory and immune reactions, a trans-
genic mouse has been generated
wherein FLuc is expressed under the
regulation of an NF-kB response ele-
ment (pNF-kB/FLuc) (Carlsen et al.,2002). With this animal model, the re-
searchers were able to analyze gross
spatial changes in NF-kB activity
before and at different times after ad-
ministration of classical stressors,
such as tumor necrosis factor a (TNF-
a), interleukin-1a (IL-1a), LPS, UV-in-
duced genotoxic stress, and induction
of a chronic inflammatory reaction re-
sembling rheumatoid arthritis. In this
way, organ-specific responses could
be mapped and analyzed on an indi-
vidual basis in cohorts of mice over
time.
Imaging post-transcriptional events
such as translational regulation, pro-
tein-protein interactions (PPI), protein
processing, or protein degradation is
primarily obtained by fusing the re-
porter gene, a partial reporter frag-
ment, or an upstream transactivator
to the protein of interest, thereby gen-
erating a molecular sensor that acti-
vates (or deactivates) the reporter in
response to a given protein interaction
or modification. For example, we
recently demonstrated that an IkBa-
FLuc fusion reporter can be used to
directly monitor in vivo the activity
of IKK, a central regulator of NF-kB ac-
tivity (Figure 1E; Gross and Piwnica-
Worms, 2005a). Here, activation of
the canonical NF-kB pathway is de-
pendent on IKK-induced phosphoryla-
tion of IkBa, an inhibitory protein that
under normal circumstances seques-
ters NF-kB in the cytoplasm. Phos-
pho-IkBa is then polyubiquitinylated
and degraded by the 26S proteasome,
allowing nuclear translocation of NF-
kB to regulate transcription of its target
genes. Indeed, after hepatocellular
delivery of the reporter, a decrease in
bioluminescence was observed in
real-time in response to LPS-mediated
activation of IKK in vivo. Applying this
approach to a tumor xenograft model
expressing the IkBa-FLuc fusion re-
porter, robust time- and dose-depen-
dent pharmacodynamic characteriza-
tion of a novel IKK inhibitor (PS-1145)
was characterized with a minimal
number of animals.
Protein-protein interactions (PPI)
play a pivotal role in signal transduction
and are now recognized as an
attractive target for pharmacological in-
tervention. Over the last five years, sev-
eral strategies have been developed forImmunity 2imaging PPI in vivo including (1) PPI-
dependent reporter gene transactiva-
tion or repression (two-hybrid systems;
recruitment of signal transduction cas-
cades), (2) energy transfer techniques
such as Fo¨rster or bioluminescence
resonance energy transfer (FRET or
BRET, respectively), and (3) reporter
complementation, achieved by fusing
inactive reporter fragments to interact-
ing proteins, which upon association
bring the fragments in close proximity
and restore reporter activity (Gross
and Piwnica-Worms, 2005b). Re-
cently, an optimized FLuc protein frag-
ment complementation system was
developed by screening incremental
truncation libraries of N- and C-termi-
nal fragments of FLuc (Luker et al.,
2004). With this system, quantitative
assessment of PPI was enabled in in-
tact cells and in vivo, exhibiting robust
inducibility. Indeed, drug-specific in-
duction of bioluminescence reached
1200-fold over background, exceeding
currently available systems. This prop-
erty enabled monitoring of low-affinity
PPI and allowed analysis of the pres-
ence and extent of interferong- and Ja-
nus kinase-1-independent homodime-
rization of STAT1. In fact, in agreement
with several subsequent reports, the
existence of a large pool of nonphos-
phorylated STAT1 homodimers was
identified with this imaging strategy.
Overall, these innovative strategies
offer a means to accurately analyze
the dynamic nature of cell-cell, cell-
antigen, and cell-humoral factor inter-
actions, as well as a means to detect
intracellular signaling and host-patho-
gen interactions, all within the complex
immunologic environment of the intact
animal. Integration of smart probes
and reporters with animal models of
immune disorders will enable immu-
nologists to address complex para-
digms such as regulation of hemato-
poiesis, trafficking and activation of
immune cells, differentiation of stem
cells, and interaction between immune
cells and stromal cells on microscopic
and macroscopic scales and in four
dimensions.
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